N
SKBI

Natixis’s SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) SKBI Stock Holding History

Natixis’s Portfolio SKBI Stock Details SKBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-16,012
Closed -$56K – 631
2013
Q4 		$56K Buy
+16,012
New +$70.7K ﹤0.01% 530

Other funds holding SKBI

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACM
Ativo Capital Management Chicago, Illinois $115M AUM 19.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Natixis's SKBI Position: Q1 2014 in Review

Natixis sold out of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) in Q1 2014, closing a stake of 16,012 shares — an estimated $56K sold.

Natixis first reported a position in SKBI in Q4 2013 and held it in 1 quarter. The position peaked at $56K in Q4 2013. 9 funds tracked by Wall St. Rank hold SKBI as of Q1 2014.

  • Natixis reported no remaining SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position as of Q1 2014 after selling out during the quarter.
  • Natixis sold 16,012 SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) shares in Q1 2014, an estimated $56K.
  • Natixis first reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in Q4 2013 and held it in 1 quarter.
  • Natixis's SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position peaked at $56K in Q4 2013.
  • 9 funds tracked by Wall St. Rank held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) as of Q1 2014.

Based on Natixis's 13F filing for Q1 2014, filed 14 May 2014.